Recombinant tumour necrosis factor alpha administered subcutaneously or intramuscularly for treatment of advanced malignant disease: a phase I trial

This publication has 15 references indexed in Scilit:

• Cytokines as communication signals between leukocytes and endothelial cells
  Immunology Today, 1989
• Intralesional application of recombinant human tumor necrosis factor alpha induces local tumor regression in patients with advanced malignancies
  European Journal of Cancer and Clinical Oncology, 1989
• Enhanced Serum Levels of β-2-Microglobulin, Neopterin, and Interferon-γ in Patients Treated with Recombinant Tumor Necrosis Factor-α
  Journal of Interferon Research, 1988
• Lymphocyte function-associated antigen-1 (LFA-1) interaction with intercellular adhesion molecule-1 (ICAM-1) is one of at least three mechanisms for lymphocyte adhesion to cultured endothelial cells.
  The Journal of cell biology, 1988
• Modulation of tumor necrosis factor-α cytotoxicity in L929 cells by bacterial toxins, hydrocortisone and inhibitors of arachidonic acid metabolism
  Biochemical and Biophysical Research Communications, 1987
• Tumour necrosis factor as immunomodulator and mediator of monocyte cytotoxicity induced by itself, γ-interferon and interleukin-1
  Nature, 1986
• Cachectin and tumour necrosis factor as two sides of the same biological coin
  Nature, 1986
• Recombinant Human Tumor Necrosis Factor-α: Effects on Proliferation of Normal and Transformed Cells in Vitro
  Science, 1985
• Tumor Necrosis Factor (TNF)
  Science, 1985
• Identity of tumour necrosis factor and the macrophage-secreted factor cachectin
  Nature, 1985